Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.39 |
| ▸ | PDE1C | Q14123 | 5/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.39 |
| ▸ | PDE1A | P54750 | 3/20 | 0.38 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.36 |
| ▸ | ASPH | Q12797 | 1/20 | 0.35 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.35 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2287748 | 0.82 | PIK3C3 (0.40) | BRD4PDE1CGRM2PDE1APDE1B | |
| SCHEMBL12409687 | 0.80 | PIK3C3 (0.38) | BRD4PDE1CGRM2PDE1APDE1B | |
| SCHEMBL12376658 | 0.79 | CNR2 (0.37) | BRD4PDE1CGRM2PDE1APDE1B | |
| SCHEMBL27778071 | 0.79 | GRM2 (0.40) | BRD4PDE1CGRM2PDE1APDE1B | |
| SCHEMBL27778069 | 0.74 | BRD4 (0.40) | BRD4PDE1CGRM2PDE1APDE1B | |
| SCHEMBL996418 | 0.73 | GRM2 (0.48) | BRD4GRM2 | |
| SCHEMBL2281397 | 0.72 | EGLN1 (0.58) | BRD4NOTUM | |
| SCHEMBL14829162 | 0.69 | GRM2 (0.43) | GRM2NOTUM | |
| SCHEMBL5655701 | 0.68 | KCNH2 (0.40) | BRD4PDE1CPDE1APDE1BPIK3C3 | |
| SCHEMBL1078962 | 0.68 | KDM4C (0.45) | BRD4GRM2KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| CN-101522687-A | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA INC (US) | 2009-09-02 | — | — | CN | disclosed |
| EP-1989211-A2 | HETEROBICYCLIC THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER | Array Biopharma, Inc. (US) | 2008-11-12 | — | — | EP | disclosed |
| WO-2008063202-A2 | HETEROBICYCLIC THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER | ARRAY BIOPHARMA INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | BRD4 4102/4885PDE1C 930/4885GRM2 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.